A. Khan

发表

Onset of response in relation to outcome in depressed outpatients with placebo and imipramine.

S. Dager, D. Dunner, D. Avery, 1989, Journal of affective disorders.

Efficacy and safety of venlafaxine extended release in children and adolescents with generalised anxiety disorder

L. W. Lamm, N. R. Kunz, A. Khan, 2002, European Neuropsychopharmacology.

Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration Database.

W. Brown, A. Khan, S. Khan, 2001, The international journal of neuropsychopharmacology.

Therapeutic role of a psychiatric intensive care unit in acute psychosis.

J. Chiles, A. Khan, S. Cohen, 1987, Comprehensive psychiatry.

Chronicity of depressive episode in relation to antidepressant-placebo response.

S. Dager, D. Dunner, D. Avery, 1991, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

Delusional depression. Phenomenology, Neuroendocrine function, and tricyclic antidepressant response.

A. Khan, W. H. Nelson, W. Orr, 1984, Journal of affective disorders.

Characteristics of placebo response during long-term treatment of panic disorder.

S. Dager, D. Dunner, D. Avery, 1990, Psychopharmacology bulletin.

Predictors of response to electroconvulsive therapy: A new role for tissue-type plasminogen activator and plasminogen activator inhibitor 1

H. Frieling, S. Bleich, A. Neyazi, 2019, European Neuropsychopharmacology.

Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart-review study.

K. Phillips, J. Siniscalchi, A. Khan, 2001, The Journal of clinical psychiatry.

Increase in plasma levels of clozapine and norclozapine after administration of nefazodone.

S. Preskorn, A. Khan, 2001, The Journal of clinical psychiatry.

Tardive dyskinesia in the mentally retarded: comparison of prevalence, risk factors and topography with a schizophrenic population

J. Chiles, A. Khan, S. Cohen, 1991, Acta psychiatrica Scandinavica.

Significance of mixed features in acute mania.

A. Khan, S. Cohen, J. Robison, 1988, Comprehensive psychiatry.

Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database.

W. Brown, Arif Khan, A. Khan, 2000, Archives of general psychiatry.

Mood stabilisation with lamotrigine in rapid cycling bipolar disorder

L. Altshuler, R. Post, J. Zajecka, 2000, European Neuropsychopharmacology.

Pharmacological management of manic psychosis in an unlocked setting.

S. Johnson, A. Khan, S. Cohen, 1987, Journal of clinical psychopharmacology.

Factors associated with chronic depressive episodes: a preliminary report from the STAR‐D project

A. Rush, M. Trivedi, S. Wisniewski, 2005, Acta psychiatrica Scandinavica.

Effect of Ramadan Fasting on Cognitive Functions Using P300 Event Related Potential and the Cancellation Test

N. Dolu, H. Yapislar, A. Khan, 2018 .

Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the food and drug administration database.

W. Brown, Arif Khan, A. Khan, 2001, The American journal of psychiatry.

Bright light treatment of winter depression: morning versus evening light

S. Dager, D. Avery, G. Cox, 1990, Acta psychiatrica Scandinavica.

Dexamethasone suppression test in recently detoxified alcoholics: clinical implications.

J. Becker, D. Ciraulo, J. Jaffe, 1984, Journal of clinical psychopharmacology.

Adinazolam--a new antidepressant: findings of a placebo-controlled, double-blind study in outpatients with major depression.

D. Dunner, D. Avery, A. Khan, 1987, Journal of clinical psychopharmacology.

Ssris and Deliberate Self-harm Ssris and Deliberate Self-harm

D. Healy, W. Brown, S. Montgomery, 2022 .

Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials

N. Polissar, A. Khan, E. Shankles, 2002, International clinical psychopharmacology.

The placebo enigma in antidepressant clinical trials.

W. Brown, A. Khan, 2001, Journal of clinical psychopharmacology.

Antipsychotic effect of milieu in the acute treatment of schizophrenia.

A. Khan, S. Cohen, 1990, General hospital psychiatry.

Adjunctive benzodiazepines in acute schizophrenia.

A. Khan, S. Cohen, 1987, Neuropsychobiology.

Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder.

M. Trivedi, R. Berman, A. Pikalov, 2011, The Journal of clinical psychiatry.

Who should receive antidepressants: suggestions from placebo treatment.

W. Brown, A. Khan, 1991, Psychopharmacology bulletin.

P.645 Immune cell-type specific methylation of tissue-type plasminogen activator in patients receiving electroconvulsive therapy

H. Frieling, S. Bleich, A. Neyazi, 2019, European Neuropsychopharmacology.

Hospitalization effect in acute mania.

D. Dunner, A. Khan, S. Cohen, 1988, General hospital psychiatry.

EPA-0120 – Validation and Normalization of the Russian Version of the Positive and Negative Syndrome Scale (PANSS-RU) in Schizophrenia: Preliminary Findings

M. Opler, A. Reznik, A. Khan, 2014, European Psychiatry.

Psychotic and nonpsychotic depression: comparison of response to ECT.

D. Avery, A. Khan, S. Cohen, 1988, The Journal of clinical psychiatry.

The dexamethasone suppression test: interaction of diagnosis, sex, and age in psychiatric inpatients.

A. Khan, R. N. Tamragouri, W. H. Nelson, 1984, Biological psychiatry.